Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp
- PMID: 17211546
- DOI: 10.1007/s00284-005-0463-6
Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp
Abstract
Monoclonal antibodies (MAbs) against lipooligosaccharide (LOS) determinants after immunization of BALB/c mice with heat inactivated Moraxella catarrhalis serotype A were generated. MAb 219A9 was specific for a common epitope of A, B, and C M. catarrhalis serotypes in ELISA and immunofluorescent test (IFT). In both tests it also cross-reacted with whole bacteria and LPS antigens isolated from non-typeable H. influenzae and H. parainfluenzae strains. IgM antibody clone 219A9 possessed a strong bactericidal effect against the three serotypes in the presence of complement. Our results demonstrate that antibodies directed to a single LOS epitope common for A, B, and C serotype could be highly protective. This suggests that the common determinants are very promising in the development of LOS-based vaccine against M. catarrhalis. The cross-reactions of MAb 219A9 with Haemophilus spp. also show that immunization could result in immune response to epitopes conserved in other important respiratory pathogens.
Similar articles
-
Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis.Infect Immun. 2001 Mar;69(3):1358-63. doi: 10.1128/IAI.69.3.1358-1363.2001. Infect Immun. 2001. PMID: 11179299 Free PMC article.
-
Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.Glycoconj J. 2011 May;28(3-4):165-82. doi: 10.1007/s10719-011-9332-7. Epub 2011 May 18. Glycoconj J. 2011. PMID: 21590368
-
Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae.Vaccine. 2020 Jan 10;38(2):309-317. doi: 10.1016/j.vaccine.2019.10.014. Epub 2019 Oct 23. Vaccine. 2020. PMID: 31668366
-
A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides.Clin Diagn Lab Immunol. 1996 May;3(3):351-4. doi: 10.1128/cdli.3.3.351-354.1996. Clin Diagn Lab Immunol. 1996. PMID: 8705682 Free PMC article.
-
Vaccines for Moraxella catarrhalis.Vaccine. 2000 Dec 8;19 Suppl 1:S101-7. doi: 10.1016/s0264-410x(00)00287-5. Vaccine. 2000. PMID: 11163472 Review.
Cited by
-
Phylogenetic Lineages and Diseases Associated with Moraxella catarrhalis Isolates Recovered from Bulgarian Patients.Int J Mol Sci. 2024 Sep 10;25(18):9769. doi: 10.3390/ijms25189769. Int J Mol Sci. 2024. PMID: 39337257 Free PMC article.
-
Potential targets for next generation antimicrobial glycoconjugate vaccines.FEMS Microbiol Rev. 2018 May 1;42(3):388-423. doi: 10.1093/femsre/fuy011. FEMS Microbiol Rev. 2018. PMID: 29547971 Free PMC article. Review.
-
A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.Hum Vaccin Immunother. 2017 Oct 3;13(10):2322-2331. doi: 10.1080/21645515.2017.1356951. Hum Vaccin Immunother. 2017. PMID: 28853985 Free PMC article. Review.
-
An Unusual Carbohydrate Conformation is Evident in Moraxella catarrhalis Oligosaccharides.Molecules. 2015 Aug 5;20(8):14234-53. doi: 10.3390/molecules200814234. Molecules. 2015. PMID: 26251889 Free PMC article.
-
Shielding of a lipooligosaccharide IgM epitope allows evasion of neutrophil-mediated killing of an invasive strain of nontypeable Haemophilus influenzae.mBio. 2014 Jul 22;5(4):e01478-14. doi: 10.1128/mBio.01478-14. mBio. 2014. PMID: 25053788 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous